Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inaleucel - Glycostem

Next Previous
X
Search
Drug Profile

Inaleucel - Glycostem

Alternative Names: Allogeneic UCB-NK cells; GCT NK cells; GTA-002; Inaleucel; Natural killer cells - Glycostem; NK cells - Glycostem; oNKord®; UCB-NK cells

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycostem
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Acute myeloid leukaemia
  • Preclinical Solid tumours
  • Research Malignant melanoma

Most Recent Events

  • 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
  • 24 Jan 2024 Inaleucel is still in preclinical development for Solid-tumours in Netherlands (IV) (Glycostem pipeline, January 2024)
  • 20 Sep 2023 Efficacy data from a phase-I/II clinical trials in Acute myeloid leukaemia presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top